{"id":"W4394015334","doi":"10.1016/j.euo.2024.03.006","title":"Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial","year":2024,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Hospital; Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Prostate cancer; Placebo; Adverse effect; Abiraterone; Internal medicine; Oncology; Enzalutamide; Prednisone; Common Terminology Criteria for Adverse Events; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002842985,0.0008592006,0.001380198,0.0002582146,0.0002314923,0.0009020151,0.0005862173,0.0007159017,0.004787318],"category_scores_gemma":[0.002481457,0.0002715945,0.002032945,0.0004921148,0.0005730456,0.0007063723,0.0003747804,0.001874455,0.0006818482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007286817,"about_ca_system_score_gemma":0.0011953,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005010494,"about_ca_topic_score_gemma":0.001433725,"domain_scores_codex":[0.9989113,0.0007693503,0.00004883201,0.00007368557,0.0001010644,0.00009574276],"domain_scores_gemma":[0.9978153,0.0006605758,0.0007630574,0.0001233237,0.0001804247,0.0004573533],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8592048,0.008767365,0.00665422,0.002377677,0.002929312,0.0002365563,0.0002116468,0.001239741,0.006671243,0.000120484,0.003727421,0.1078594],"study_design_scores_gemma":[0.7616961,0.207032,0.0227754,0.0003055446,0.001477934,0.0004107613,0.0001009792,0.000603943,0.001141126,0.0002832188,0.004126273,0.0000466799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9742802,0.01898144,0.0005083767,0.001005543,0.0001576513,0.00114846,0.001772611,0.00007656596,0.002069243],"genre_scores_gemma":[0.9884148,0.005309774,0.0008229945,0.0009687046,0.0003370458,0.0009878826,0.002217349,0.00002038072,0.0009211987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004787318,"threshold_uncertainty_score":0.01601517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03318067851103599,"score_gpt":0.3274725378897915,"score_spread":0.2942918593787555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}